[1] Enhertu demonstrated clinically meaningful and durableresponses in patients across multiple HER2-expressing advanced solid tumours. RetrievedJune 5, 2023 from https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing.html
[2] AstraZeneca, Daiichi Sankyo’s Enhertu impresses in 'game-changing'study with many cancers: #ASCO23. Retrieved June 5, 2023 from https://endpts.com/astrazeneca-daiichi-sankyos-enhertu-impresses-in-game-changing-study-with-many-cancers-asco23/
[3] Datopotamab deruxtecan combinations showed encouraging tumourresponses in patients with advanced non-small cell lung cancer inTROPION-Lung02 Phase Ib trial. Retrieved June 5, 2023 from https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-combinations-showed-encouraging-tumour-responses-in-patients.html